Miguel Ángel Saavedra

Miguel Ángel Saavedra

Auto-generated profile, based on publicly available information

Miguel Ángel Saavedra


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Pharmacological Research
Verified
Journal Article
Closed access
GMGabriela Medina
Gabriela Medina
VLVera-Lastra Olga Lidia
Vera-Lastra Olga Lidia
APAna Lilia Peralta-Amaro
Ana Lilia Peralta-Amaro
MJMaría Pilar Jiménez-Arellano
María Pilar Jiménez-Arellano
MSMiguel Angel Saavedra
Miguel Angel Saavedra
LJLuis J. Jara
Luis J. Jara

4 February 2021 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
AGAbraham Edgar Gracia-Ramos
Abraham Edgar Gracia-Ramos
MSMiguel Ángel Saavedra-Salinas
Miguel Ángel Saavedra-Salinas

7 June 2015 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
MSMiguel Ángel Saavedra
Miguel Ángel Saavedra
ASAntonio Sánchez
Antonio Sánchez
SMSara Morales
Sara Morales
UÁUlises Ángeles
Ulises Ángeles
LJLuis Javier Jara
Luis Javier Jara

15 November 2021 in Rheumatology International
Verified
Journal Article
Open access
PDF file
PSParikshit Sen
Parikshit Sen
LGLatika Gupta
Latika Gupta
JLJames B. Lilleker
James B. Lilleker
VAVishwesh Agarwal
Vishwesh Agarwal
SKSinan Kardes
Sinan Kardes
RARohit Aggarwal
Rohit Aggarwal
The coronavirus disease-2019 (COVID-19) pandemic continues to be a cause of unprecedented global morbidity and mortality. Whilst COVID-19 vaccination has emerged as the only tangible solution to reducing poor clinical outcomes, vaccine hesitancy continues to be an obstacle to achieving high levels of vaccine uptake. This represents particular risk to patients with autoimmune diseases, a group already at increased risk of hospitalization and poor clinical outcomes related to COVID-19 infection. Whilst there is a paucity of long-term safety and efficacy data of COVID-19 vaccination in patients with autoimmune diseases, the current evidence strongly suggests that the benefits of vaccination outweigh the risks of adverse effects and disease flares. Herein, we report the protocol of the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study, an ongoing international collaborative study involving 29 countries and over 110 investigators.

8 August 2022 in Muscle & Nerve
Verified
Journal Article
Open access
AGAlbert Gil‐Vila
Albert Gil‐Vila
NRNaveen Ravichandran
Naveen Ravichandran
ASAlbert Selva-O'Callaghan
Albert Selva-O'Callaghan
PSParikshit Sen
Parikshit Sen
Arvind NuneArvind Nune
Arvind Nune
CGCOVAD Study Group
COVAD Study Group
Introduction/Aims: In this study we investigated COVID‐19 vaccination–related adverse events (ADEs) 7 days postvaccination in patients with idiopathic inflammatory myopathies (IIMs) and other systemic autoimmune and inflammatory disorders (SAIDs).Methods: Seven‐day vaccine ADEs were collected in an international patient self‐reported e‐survey. Descriptive statistics were obtained and multivariable regression was performed.Results: Ten thousand nine hundred respondents were analyzed (1227 IIM cases, 4640 SAID cases, and 5033 healthy controls [HCs]; median age, 42 [interquartile range, 30‐455] years; 74% female; 45% Caucasian; 69% completely vaccinated). Major ADEs were reported by 76.3% of the IIM patients and 4.6% reported major ADEs. Patients with active IIMs reported more frequent major (odds ratio [OR], 2.7; interquartile range [IQR], 1.04‐7.3) and minor (OR, 1.5; IQR, 1.1‐2.2) ADEs than patients with inactive IIMs. Rashes were more frequent in IIMs (OR, 2.3; IQR, 1.2‐4.2) than HCs. ADEs were not impacted by steroid dose, although hydroxychloroquine and intravenous/subcutaneous immunoglobulins were associated with a higher risk of minor ADEs (OR, 1.9; IQR, 1.1‐3.3; and OR, 2.2; IQR, 1.1‐4.3, respectively). Overall, ADEs were less frequent in inclusion‐body myositis (IBM) and BNT162b2 (Pfizer) vaccine recipients.Discussion: Seven‐day postvaccination ADEs were comparable in patients with IIMs, SAIDs, and HCs, except for a higher risk of rash in IIMs. Patients with dermatomyositis with active disease may be at higher risk, and IBM patients may be at lower risk of specific ADEs. Overall, the benefit of preventing severe COVID‐19 through vaccination likely outweighs the risk of vaccine‐related ADEs. Our results may inform future guidelines regarding COVID‐19 vaccination in patients with SAIDs, specifically in those with IIMs. Studies to evaluate long‐term outcomes and disease flares are needed to shed more light on developing future COVID‐19 vaccination guidelines.

14 August 2022 in Rheumatology International
Verified
Journal Article
Open access
PDF file
ZFZoha Zahid Fazal
Zoha Zahid Fazal
PSParikshit Sen
Parikshit Sen
MJMrudula Joshi
Mrudula Joshi
NRNaveen Ravichandran
Naveen Ravichandran
JLJames B. Lilleker
James B. Lilleker
LGLatika Gupta
Latika Gupta
Vaccine hesitancy is considered a major barrier to achieving herd immunity against COVID-19. While multiple alternative and synergistic approaches including heterologous vaccination, booster doses, and antiviral drugs have been developed, equitable vaccine uptake remains the foremost strategy to manage pandemic. Although none of the currently approved vaccines are live-attenuated, several reports of disease flares, waning protection, and acute-onset syndromes have emerged as short-term adverse events after vaccination. Hence, scientific literature falls short when discussing potential long-term effects in vulnerable cohorts. The COVAD-2 survey follows on from the baseline COVAD-1 survey with the aim to collect patient-reported data on the long-term safety and tolerability of COVID-19 vaccines in immune modulation. The e-survey has been extensively pilot-tested and validated with translations into multiple languages. Anticipated results will help improve vaccination efforts and reduce the imminent risks of COVID-19 infection, especially in understudied vulnerable groups.